Please use this identifier to cite or link to this item:
Title: Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer
Authors: Li, Y.
Li, Y.
Wedrén, S.
Li, G.
Charn, T.H.
Desai, K.V.
Bonnard, C.
Czene, K.
Humphreys, K.
Darabi, H.
Einarsdóttir, K.
Heikkinen, T.
Aittomäki, K.
Blomqvist, C.
Chia, K.S. 
Nevanlinna, H.
Hall, P.
Liu, E.T.
Liu, J.
Issue Date: 26-Jan-2011
Source: Li, Y., Li, Y., Wedrén, S., Li, G., Charn, T.H., Desai, K.V., Bonnard, C., Czene, K., Humphreys, K., Darabi, H., Einarsdóttir, K., Heikkinen, T., Aittomäki, K., Blomqvist, C., Chia, K.S., Nevanlinna, H., Hall, P., Liu, E.T., Liu, J. (2011-01-26). Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Research 13 (1) : -. ScholarBank@NUS Repository.
Abstract: Introduction: Given the role of estrogen in breast carcinogenesis and the modification of estrogen receptor (ER) activity by its biochemical cofactors, we hypothesize that genetic variation within ER cofactor genes alters cellular response to estrogen exposure and consequently modifies the risk for ER-positive breast cancer.Methods: We genotyped 790 tagging SNPs within 60 ER cofactor genes in 1,257 cases and 1,464 controls from Sweden and in 2,215 cases and 1,265 controls from Finland, and tested their associations with either ER-positive or ER-negative breast cancer.Results: Seven SNPs showed consistent association with ER-positive breast cancer in the two independent samples, and six of them were located within PPARGC1B, encoding an ER co-activator, with the strongest association at rs741581 (odds ratio = 1.41, P = 4.84 × 10 -5) that survived Bonferroni correction for multiple testing in the combined ER-positive breast cancer sample (P corrected = 0.03). Moreover, we also observed significant synergistic interaction (P interaction = 0.008) between the genetic polymorphisms within PPARGC1B and ESR1 in ER-positive breast cancer. By contrast, no consistent association was observed in ER-negative breast cancer. Furthermore, we found that administration of estrogen in the MCF-7 cell line induced PPARGC1B expression and enhanced occupancies of ER and RNA polymerase II within the region of SNP association, suggesting the upregulation of PPARGC1B expression by ESR1 activation.Conclusions: Our study revealed that DNA polymorphisms of PPARGC1B, coding a bona fide ER co-activator, are associated with ER-positive breast cancer risk. The feed-forward transcriptional regulatory loop between PPARGC1B and ESR1 further augments their protein interaction, which provides a plausible mechanistic explanation for the synergistic genetic interaction between PPARGC1B and ESR1 in ER-positive breast cancer. Our study also highlights that biochemically and genomically informed candidate gene studies can enhance the discovery of interactive disease susceptibility genes. © 2011 Li et al.; licensee BioMed Central Ltd.
Source Title: Breast Cancer Research
ISSN: 14655411
DOI: 10.1186/bcr2817
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Feb 27, 2018


checked on Feb 14, 2018

Page view(s)

checked on Mar 12, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.